Overview

Price chart · mood · technical indicators

ILMN

Illumina Incstock Healthcare

Diagnostics & Research

$139.3787.00%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$73.86$155.53

Current: $139.37

Market Comparison

vs Healthcare Sector & Diagnostics & Research Industry

ILMN

+87.00%

1Y Performance

Healthcare

Sector 1Y

Diagnostics & Research

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio24.69Forward 26.45

EPS (TTM)$5.506.1% YoY

Profit margin19.4%HEALTHCARE

Market cap$20.63BLarge cap

Wall Street coverage

$138.94median target· current $115.74 (+20.0%)18 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 26.45
PEG ratio: 2.47
P/B: 7.71
P/S (TTM): 4.70
EV/EBITDA: 18.45

Profitability & growth

ROE (TTM): 33.8%
Operating margin: 19.7%
Revenue growth YoY: 4.8%
Dividend yield: —
Beta: 1.49

Last earnings

Apr 28, 2026 · Estimate $1.07 · Reported $1.15

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Illumina Inc

Company profile

Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.

Classification

Sector: Healthcare
Industry: Diagnostics & Research
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 5200 ILLUMINA WAY, SAN DIEGO, CA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$20.63B

Shares outstanding$151.9M

52W high$155.53

52W low$73.86

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

ILMN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR)

Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN

Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises

|Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B

[8-K] ILLUMINA, INC. Reports Material Event

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. Stock (US4523271090): Q1 2026 Earnings Release Expected Today

Discipline and Rules-Based Execution in ILMN Response

Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics

Illumina Inc. stock outperforms competitors despite losses on the day

Illumina Inc. stock outperforms competitors on strong trading day

Human Microbiome Sequencing Technology Market Competitive Analysis to 2034 | Thermo Fisher Scientific Inc., QIAGEN N.V., Microbiome Insights Inc., Leucine Rich Bio Pvt. Ltd., Illumina, Inc etc.

Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN

Illumina Inc. stock underperforms Thursday when compared to competitors

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

OVERSEA CHINESE BANKING Corp Ltd Decreases Stock Position in Illumina, Inc. $ILMN

Gene Expression Analysis Market Set for Robust Growth to USD 11.25 Billion by 2033, Driven by Precision Medicine and Genomics Advancements, with Thermo Fisher Scientific Inc., Illumina Inc., and QIAGEN N.V. Leading the Competitive Landscape

Illumina Inc. stock underperforms Friday when compared to competitors despite daily gains

Illumina Inc. stock outperforms competitors on strong trading day

About Illumina Inc

Classification

Company profile

ILMN

Market Comparison

ILMN Market Analysis

Overview

ILMN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR)

Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN

Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises

|Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B

[8-K] ILLUMINA, INC. Reports Material Event

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. Stock (US4523271090): Q1 2026 Earnings Release Expected Today

Discipline and Rules-Based Execution in ILMN Response

Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics

Illumina Inc. stock outperforms competitors despite losses on the day

Illumina Inc. stock outperforms competitors on strong trading day

Human Microbiome Sequencing Technology Market Competitive Analysis to 2034 | Thermo Fisher Scientific Inc., QIAGEN N.V., Microbiome Insights Inc., Leucine Rich Bio Pvt. Ltd., Illumina, Inc etc.

Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN

Illumina Inc. stock underperforms Thursday when compared to competitors

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

OVERSEA CHINESE BANKING Corp Ltd Decreases Stock Position in Illumina, Inc. $ILMN

Gene Expression Analysis Market Set for Robust Growth to USD 11.25 Billion by 2033, Driven by Precision Medicine and Genomics Advancements, with Thermo Fisher Scientific Inc., Illumina Inc., and QIAGEN N.V. Leading the Competitive Landscape

Illumina Inc. stock underperforms Friday when compared to competitors despite daily gains

Illumina Inc. stock outperforms competitors on strong trading day

About Illumina Inc

Classification

Company profile

ILMN

Market Comparison